Funding for this research was provided by:
Foundation for the National Institutes of Health (K08CA230188)
Received: 16 December 2021
Accepted: 13 September 2022
First Online: 26 October 2022
: A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Allogene Therapeutics and Merck Research Laboratories. H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio and Cartography Biosciences and an advisor to 10x Genomics, Arsenal Biosciences and Spring Discovery. K.E.Y. is a consultant for Cartography Biosciences. J.A.B. is a consultant for Immunai. E.J.W. is an advisor for Danger Bio, Marengo, Janssen, NewLimit Inc., Pluto Immunotherapeutics, Related Sciences, Rubius Therapeutics, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences. The remaining authors declare no competing interests.